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Abstract: Paliperidone palmitate is a new long-acting antipsychotic injection for the treatment 
of acute and maintenance therapy in schizophrenia. Paliperidone (9-hydroxyrisperidone) is the 
major active metabolite of risperidone and acts at dopamine D2 and serotonin 5HT2A receptors. 
As with other atypical antipsychotics, it exhibits a high 5HT2A:D2 affinity ratio. It also has bind-
ing activity as an antagonist at α1- and α2 adrenergic receptors and H1 histaminergic receptors, 
but has virtually no affinity for cholinergic receptors. Paliperidone palmitate has been shown to 
be effective in reducing Positive and Negative Syndrome Scale total scores in four short-term 
trials in acute schizophrenia. It was also effective as maintenance therapy in a long-term trial in 
which time to recurrence of symptoms was significantly longer in paliperidone-treated patients 
compared with placebo. In addition, paliperidone was shown to be noninferior to risperidone 
long-acting injection in one study, but this noninferiority was not established in another   longer 
study comparing the two drugs. Treatment should be initiated with 234 mg on day 1 and 156 mg 
on day 8, followed by a recommended monthly maintenance dose of 39–234 mg based on effi-
cacy and tolerability. Paliperidone palmitate is generally well tolerated, although it can cause 
weight gain and a rise in prolactin levels, which is generally greater in women than in men. 
Overall, paliperidone palmitate may have advantages over other currently available long-acting 
injections, and therefore may be a useful alternative for the treatment of schizophrenia, although 
further long-term trials comparing it with active treatments are warranted.
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Introduction
Poor compliance with medication remains a major cause for concern in the manage-
ment of schizophrenia. It has been shown that more than 35% of patients experience 
compliance problems within the first few weeks of therapy, and only 25% are fully 
compliant after two years.1 A combination of factors may contribute to this problem, 
including lack of insight, negative symptoms, cognitive decline, and poor tolerability 
of available agents. These have a major negative impact on compliance which, in turn, 
leads to considerable risk of relapse, thus reducing the likelihood of full recovery to 
the baseline level of functioning.1
Conventional antipsychotic depot formulations were first introduced in the 1960s 
as a means to improve compliance with therapy. However, the negative symptoms 
of schizophrenia are not adequately managed by these older drugs, and their high 
propensity to cause extrapyramidal symptoms and raised prolactin levels has limited 
their use over time. Of late, after many years of research and development, pharma-
ceutical companies have also succeeded in formulating certain atypical   antipsychotics Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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into   long-acting injections. Risperidone was the first atypical 
agent to be formulated as a long-acting injection, adminis-
tered every two weeks. However, supplementary oral treat-
ment is required for the first 4–6 weeks of intramuscular 
therapy due to the delay in reaching steady-state plasma 
levels. In addition, although the three licensed doses (25 mg, 
37.5 mg, and 50 mg every two weeks) have been shown to 
be equally effective in clinical trials, the lowest dose (25 mg 
every two weeks) has been shown to be relatively less effec-
tive in practice.2
Olanzapine has also been recently formulated into a 
pamoate suspension for intramuscular administration every 
2–4 weeks. With this product, a safety risk emerged during 
clinical trials known as “post-injection syndrome”, consist-
ing of an unexpected high degree of sedation, confusion, 
dizziness, altered speech, and/or unconsciousness occur-
ring in a small number of patients following injection.3 The 
incidence of this has been estimated as 1.2% of patients 
treated, or 0.07% of injections given.4 The formulation went 
on to gain its license despite this adverse effect, but with 
the recommendation that a three-hour patient observation 
period follow each injection, a restriction that will most 
likely limit its use for practical reasons, as well as the safety 
issues involved.4
While the introduction of atypical antipsychotic drugs 
has been of some benefit to patients, the use of these new 
agents has been accompanied by serious adverse effects 
also limiting their clinical use. Atypical antipsychotics have 
been implicated in the development of metabolic disorder,5 
consisting of raised cholesterol and triglycerides alongside 
impaired glucose tolerance.6 The likelihood of experiencing 
these adverse effects varies amongst the different drugs in this 
class. Furthermore, considerable weight gain7 is an additional 
risk, often leading to early treatment discontinuation and poor 
compliance with therapy. As a result, despite the increasing 
number of agents being developed for the management of 
schizophrenia, there are still many individuals who are not 
receiving adequate benefit or not able to tolerate currently 
available agents. The introduction of paliperidone once-
monthly injections is therefore a welcome addition to the 
market. In this paper, the pharmacology, pharmacokinetics, 
efficacy, and safety of paliperidone palmitate are reviewed, 
and its potential place in the treatment of schizophrenia is 
discussed.
Paliperidone palmitate
Paliperidone palmitate is the most recent atypical antip-
sychotic to be developed as a long-acting injection and 
was approved by the US Food and Drug Administration 
in August 2009 for acute and maintenance therapy in adult 
patients with schizophrenia. A marketing authorization 
application has been submitted to the European Medicines 
Agency, whereby following approval, it will be marketed 
in Europe, and marketing applications in other areas of the 
world are ongoing.
Pharmacology
Paliperidone, also described as 9-hydroxyrisperidone, is the 
major active metabolite of risperidone. Its pharmacology 
and mechanism of action are therefore believed to be similar 
to that of risperidone. Paliperidone acts as an antagonist at 
dopamine D2 and serotonin 5HT2A receptors, exhibiting a high 
5HT2A:D2 affinity ratio, as with other atypical agents.8 It also 
has binding activity as an antagonist at α1- and α2-adrenergic 
receptors and H1-histaminergic receptors, but has virtually no 
affinity for cholinergic receptors.8–10 Paliperidone’s activity 
profile suggests that it has the potential to cause orthostatic 
hypotension, weight gain, and sedation. However, because it 
has no antagonistic activity at cholinergic receptors, it has a 
low propensity to cause anticholinergic adverse effects and 
cognitive impairment.
Pharmacokinetics
Paliperidone palmitate is a benzisoxazole derivative which is 
hydrolyzed to the active moiety, paliperidone, and absorbed 
into the systemic circulation (see Figure 1). The palmitate 
ester of paliperidone is an aqueous suspension which utilizes 
nanoparticle technology. The resulting increased surface 
area leads to rapid release of medication and therefore a 
relatively short time to steady state. Following an injection, 
active paliperidone plasma levels have been detected from 
day 1, therefore coadministration with oral paliperidone on 
initiation of therapy is not required. Following the intramus-
cular administration of single doses in the deltoid muscle, 
on average a 28% higher peak concentration is observed 
compared with injection in the gluteal muscle. However, 
after four injections, there is no difference between the time 
to maximum plasma concentration and area under the curve 
between the two injection sites.11,12 Thus, the two initial del-
toid muscle injections on days 1 and 8 (see Table 1) help to 
attain therapeutic drug concentrations rapidly.13
Paliperidone is largely excreted unchanged in the urine. 
Four metabolic pathways have been identified for the metabo-
lism of paliperidone including dealkylation, hydroxylation, 
dehydrogenation, and benzisoxazole scission, although none 
accounted for more than 10% of the oral dose administered.13 Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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While cytochrome P450 (CYP) 2D6 and CYP3A4 have been 
implicated in the metabolism of paliperidone in in vitro studies, 
these isoenzymes play a limited role in the metabolism of pali-
peridone in vivo. The nanocrystal molecules which make up the 
paliperidone palmitate suspension also allow it to undergo slow 
dissolution, yielding a half-life of 25–49 days (see Table 2).13–16 
The relatively long half-life allows for the monthly administra-
tion of paliperidone intramuscular injections.
Efficacy in schizophrenia
Efficacy in clinical trials
The therapeutic efficacy of paliperidone palmitate once-
monthly injection has been evaluated in four short-term 
(nine- and 13-week) multicenter, randomized, double-blind, 
placebo-controlled trials in acute schizophrenia.14,17–19 In all 
four trials, the injection was administered on days 1, 8, and 
36 and, in the 13-week trials, also on day 64. Paliperidone 
palmitate’s efficacy as maintenance therapy in schizophrenia 
has also been evaluated in a 52-week recurrence prevention 
study20 and a further 52-week, open-label extension phase of 
this study.21 In addition, two studies compared its clinical effi-
cacy with intramuscular long-acting risperidone injection.22,23 
Many of these studies are currently only available as poster 
presentations. The main efficacy findings from the trials are 
summarized below (and also in Table 3).
Acute efficacy
The primary efficacy endpoint in all studies was the mean 
change in Positive and Negative Syndrome Scale (PANSS) 
total score24 from baseline to endpoint. Secondary endpoints 
included changes in Clinical Global Impression of Severity 
(CGI-S),25 PANSS factor and subscale scores, and Personal 
and Social Performance Scale (PSP).26
In the largest dose-response study, intramuscular pali-
peridone was effective in the treatment of adult patients with 
acute schizophrenia, producing significant (P # 0.034) and 
dose-related changes in PANSS total score from baseline for 
each of the three paliperidone groups (39, 156, and 234 mg) 
compared with placebo.18 A significant change in PANSS 
total score was observed as early as day 8 for paliperidone 
39 and 234 mg and from day 22 for paliperidone 156 mg, 
and was maintained until the endpoint. Significantly more 
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Figure 1 Formation of paliperidone from paliperidone palmitate.
Table 1 Paliperidone palmitate injection dose and administration 
information13
Initiation Dose Administration route
Day 1 234 mg Deltoid muscle only
Day 8 (±2 days) 156 mg Deltoid muscle only
Maintenance
From Day 36 every 
four weeks (±7 days)
39–234 mg either gluteal or deltoid 
muscle
Equivalent paliperidone dosages
Oral (mg/day) intramuscular (every four weeks)
2 39 mg (25 mg eq)
4 78 mg (50 mg eq)
6 117 mg (75 mg eq)
9 156 mg (100 mg eq)
12 234 mg (150 mg eq)
Notes: Although commercially available product dosage strengths of paliperidone 
palmitate are labeled in milligrams (mg) of paliperidone, all current published poster 
presentations and clinical trials have doses reported as milligram equivalents (mg eq) 
of paliperidone.
Abbreviation: mg eq, milligram equivalents.
Table 2 Pharmacokinetic properties of paliperidone palmitate13–16
Median time to maximum  
plasma concentration
13 days
Plasma protein binding  
(racemic paliperidone)
74%
Mean apparent volume  
of distribution
391 L
Median apparent half-life  
(after single-dose administration)
25–49 days
Metabolism Minimal metabolism occurs in the 
liver (dose adjustment needed  
only in severe hepatic impairment)
excretion Up to 60% excreted unchanged by 
kidneys (lower doses needed  
in renal impairment)Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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patients on paliperidone responded to treatment (39 mg 
33.5%, P = 0.007; 156 mg 41.0%, P , 0.001; 234 mg 40.0%, 
P , 0.001) compared with placebo (20.0%).18
These findings are supported by two smaller, published, 
dose-response studies.14,17 In the first study, both doses of 
paliperidone (78 mg and 156 mg) produced significant 
(P # 0.001) mean changes from baseline in PANSS total 
score (-5.2 [21.5)] and -7.8 [19.4], respectively) compared 
with placebo (6.2 [18.3]).14 In the second study, significant 
changes in PANSS total score compared with placebo were 
noted with the 156 mg dose (P = 0.019) but not with the 78 mg 
dose (P = 0.19).17 No statistical comparison was performed 
for the 234 mg treatment group, therefore a dose-response 
relationship could not be ascertained from this study.
Long-term efficacy
There has also been a long-term maintenance study of 
recurrence prevention using paliperidone palmitate, which 
consisted of five phases, including a seven-day screening, 
washout, and tolerability period, a nine-week, open-label 
transition phase during which intramuscular paliperidone 
was initiated, a 24-week, open-label, maintenance phase 
with flexible dosing until week 21, a randomized, double-
blind, placebo-controlled phase of variable duration,20 and 
an optional 52-week, open-label extension phase.21 A recur-
rence event was defined as time to the first emergence of 
one or more of the following: hospitalization (for symptoms 
of schizophrenia), prespecified changes in PANSS scores 
or clinically significant deliberate self-injury or aggressive 
behavior. The primary outcome measure was time from ran-
domization to the first recurrent event. A preplanned interim 
analysis was carried out in order to minimize the number of 
patients exposed to placebo. In the interim analysis (planned 
after 68 relapse events) paliperidone palmitate was superior to 
placebo, with recurrence of events seen in 15 (10%) patients 
in the paliperidone group compared with 53 (34%) patients 
in the placebo group,20 yielding a numbers needed to treat 
of five (95% confidence interval [CI] 4–7).27
In the open-label extension phase of this study, improve-
ments from baseline to the endpoint were observed on 
PANSS, PSP, and CGI-S assessment.21 Overall improve-
ments in PANSS total scores observed during the previous 
study phases were maintained during the open-label phase 
for patients treated with paliperidone (mean ± SD of the 
change in PANSS total score -4.3 ± 15.43). The greatest 
  improvement in PANSS total score occurred in patients 
who were treated with placebo in the double-blind phase 
(-8.4 ± 19.43). Functional improvement as measured by Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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the PSP scale, also continued during the open-label phase, 
with the greatest improvement observed in patients previ-
ously on placebo in the double-blind phase (change in PSP 
score 6.0 ± 13.20). The authors reported that the majority 
of patients stayed in this open-label phase for one year, and 
demonstrated maintenance of symptoms as well as functional 
improvements.
Efficacy compared with active 
comparator
Paliperidone palmitate injection was compared with risperi-
done long-acting injection (RLAI) in a 53-week noninferiority 
study.22 Patients were randomized (1:1) to receive double-blind 
flexible doses of paliperidone 39–156 mg every four weeks by 
gluteal injection (after two initiation doses of 78 mg on days 
1 and 8) or RLAI 25, 37.5, or 50 mg every two weeks. Oral 
supplementation with risperidone was provided to the RLAI 
patients (as well as a placebo injection on day 1), and matched 
paliperidone patients received oral placebo and two-weekly 
placebo injections to coincide with RLAI frequency.
Although both agents resulted in decreases in PANSS 
total score (-12 ± 21.2 for paliperidone and  -14 ± 19.8 for 
RLAI), paliperidone was not shown to be noninferior to RLAI, 
based on the predetermined margin of 5 points. Least-squares 
means change in PANSS total score was 2.6 points lower (95% 
CI –5.84, 0.61) for RLAI compared with paliperidone. As 
such, the predetermined margin for noninferiority (lower limit 
of the 95% CI should be greater than -5 points) was not met 
(by 0.84 points). However, the authors concluded that noninfe-
riority was not established because patients had been initiated 
with suboptimal initial dosing of paliperidone, substantially 
lower than the initiation doses currently recommended in the 
product labeling. Therefore, this may have resulted in lower 
plasma concentrations until day 260 compared with those in 
the RLAI group. In addition, the authors believed that utiliza-
tion of the gluteal initiation site may have also led to lower 
plasma levels of paliperidone, because this site of administra-
tion is associated with lower initial exposure.
Consequently, another noninferiority study between pali-
peridone palmitate and RLAI was performed, acknowledging 
the optimized initiation dosing regimen for paliperidone.23 
This was a randomized (1:1), double-blind, double-dummy, 
  active-controlled, parallel-group, 13-week comparative Phase III 
study. Paliperidone deltoid injections of 234 mg on day 1 and 
156 mg on day 8 were given, followed by once-monthly flexible 
dosing (78–234 mg) as either deltoid or gluteal injections (and 
placebo injections matched to RLAI). The other group received 
RLAI starting at 25 mg on day 8, followed by biweekly injec-
tions which could be increased up to 37.5 mg on day 36 and 
up to 50 mg on day 64 (and placebo injections matched to the 
paliperidone initiation regimen). Patients on RLAI received oral 
risperidone supplementation (1–6 mg from days 1–28), while 
the paliperidone group received a matching oral placebo.
The primary endpoint was the change in PANSS total score 
from baseline to the double-blind endpoint.   Noninferiority 
of paliperidone compared with RLAI was to be   concluded 
if the lower limit of the two-sided 95% CI exceeded -5. 
Additional secondary endpoints included PANSS subscales, 
CGI-S, and PSP. Unlike the previous study, the lower limit 
of the 95% CI of the treatment difference for the change 
in PANSS total score did exceed the prespecified protocol 
noninferiority margin of -5, and therefore paliperidone was 
shown to be noninferior to RLAI (point estimate [95% CI] 
0.4 [-1.62; 2.38]). In addition, both groups showed similar 
improvements in CGI-S and PSP, as well as other secondary 
measures.23 Limitations of this study include its relatively 
short duration, lasting only 13 weeks compared with 53 weeks 
in the previous one, and therefore the longer-term efficacy 
of paliperidone palmitate cannot be compared with RLAI 
from these findings. Furthermore, doses above 25 mg were 
not allowed in the RLAI group for several weeks, despite 
evidence to show that RLAI 25 mg may be ineffective in 
the majority of patients.2 In fact, many patients in clinical 
practice nowadays are being initiated on 37.5 mg of RLAI, 
and the higher doses are generally used a lot sooner in the 
therapeutic regimen.
Safety and tolerability
The safety and tolerability of paliperidone palmitate were also 
assessed in the studies already described. The main findings 
are summarized in this section (and in Table 4). Treatment 
emergent adverse effects (TEAEs) occurring more frequently 
in the paliperidone palmitate groups than in the placebo group 
included insomnia, headache, dizziness, sedation, vomiting, 
schizophrenia, injection site pain, extremity pain, myalgia, 
and extrapyramidal symptoms.14,17
Safety in acute therapy
In the nine-week study, parkinsonian-type adverse effects, 
including drooling and hypertonia, were the most common 
extrapyramidal side effects, and occurred more frequently 
in the paliperidone groups than placebo.14 Other extrapy-
ramidal side effects occurred similarly in all groups and Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
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Table 4 Summary of safety studies for paliperidone palmitate
Authors Study details Number of 
patients (n)
Safety outcomes for paliperidone palmitate
Kramer et al14 rCT, DB, PC
Nine-week, efficacy and safety 
study
247 incidence of TeAes:
• Pbo: 64% 
• PP 78 mg: 65% 
• PP 156 mg: 60%
Discontinuation due to TeAes:
• Pbo: 10%
• PP 78 mg: 3%; 
• PP 156 mg: 2%  
ePS rates comparable except parkinsonism:
• Pbo: 1%
• PP 78 mg: 5% 
• PP 156 mg: 8% 
Prolactin (ng/mL), median (range), in males:
Predose: 
•   Pbo: 7.0 (1-32); PP 78 mg: 6.5 (1-35); PP 156 mg: 7.0 (2-65)
endpoint: 
•   Pbo: 6.0 (2-33); PP 78 mg: 18.0 (6-54); PP 156 mg: 
30.0 (9-93)
Prolactin (ng/mL), median (range), in females:
Predose: 
•   Pbo: 15.0 (4-242); PP 78 mg: 12.0 (3-41); PP 156 mg: 
20.0 (2-120)
endpoint: 
•   Pbo: 8.0 (3-180); PP 78 mg: 33.5 (11-769);  
PP 156 mg: 66.5 (9-228)
Mean (±SD) changes in body weight (kg) at endpoint:
• Pbo: -0.3 ± 3.0 
• PP 78 mg: 0.7 ± 2.7 (P = 0.059) 
• PP 156 mg: 1.4 ± 3.5 (P ≤ 0.001)
Mean (±SD) changes in BMi (kg/m2) at endpoint:
• Pbo: -0.1 ± 1.0 
• PP 78 mg: 0.3 ± 0.9 (P = 0.036) 
• PP 156 mg: 0.5 ± 1.2 (P # 0.001)
Hough et al28 randomized, 25-week, crossover 
study comparing deltoid and gluteal 
administration of PP 78, 117, 
and 156 mg
252 
(iTT: 249)
Overall incidence of TeAes:
• Deltoid- period 1: 64%, period 2: 51%
• Gluteal- period 1: 63%, period 2: 46%
incidence of extrapyramidal-related TeAes:
• Period 1: 7% deltoid, 10% gluteal
• Period 2: 2% deltoid, 6% gluteal
Gopal et al17 rCT, DB, PC
13 weeks
Dose-response study
388 incidence of TeAes:
• Pbo group: 76%
• PP group: 79%  
Mean increases in weight (kg) from baseline to endpoint-Mean 
change (SD): 
• Pbo: -0.7 (5.26)
• 78 mg: 1.0 (5.17) 
• 156 mg: 1.5 (3.79) 
• 234 mg: 0.9 (3.16)
Mean (SD) increase in prolactin (ng/mL) from baseline to 
endpoint:
•   Women- [Pbo: -11.21 (28.99); PP 78 mg: 32.04 (24.64); 
PP 156 mg: 40.17 (48.07); PP 234 mg: 62.33 (29.32)]
•   Men- [Pbo: 1.20 (9.99); PP 78 mg: 7.13 (10.33);  
PP 156 mg: 15.10 (13.92); PP 234 mg: 15.21 (14.08)]
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Table 4 (Continued)
Authors Study details Number of 
patients (n)
Safety outcomes for paliperidone palmitate
Pandina et al18 rCT, DB, PC 13 weeks
Dose-response study
652 Similar TeAe rates:
• Pbo group: 65%
• PP group: 60–63%  
Weight increase of (7%) occurred in:
• Pbo: 5%  
• PP: 39 mg: 6% 
• PP: 156 mg: 8% 
• PP: 234 mg: 13%
Mean increase in prolactin levels from baseline:
PP groups
• Women: 4.72–37.24 ng/mL
• Men: 3.73–13.15 ng/mL
Pbo: prolactin levels decreased in both sexes
Hough et al20 rCT, DB, PC 
52-week study to evaluate efficacy 
in prevention of recurrence of 
symptoms
408 Abnormal weight increase (7%):
•   PP: 23% versus pbo: 12% from transition baseline to endpoint
• PP: 6% versus pbo: 3% from DB baseline to endpoint
Mean weight increased by 1.9 kg in PP group but remained 
unchanged in pbo group
Blood glucose increase (2% difference):
• PP: 3% versus pbo: 1%
Mean (SD) increase in prolactin (ng/mL) during DB phase:
• Women- PP: 12.7 (28.64) versus pbo: -16.6 (28.70)
• Men- PP: 3.7 (15.70) versus pbo: -9.2 (12.36)
Gopal et al21 Open-label, extension-phase 
(see Hough et al20)
388 Weight change for total PP group: 0.9 ± 4.26 kg  
13% of patients experienced 7% weight increase at endpoint.
Prolactin levels increased in patients on PP who were on pbo in 
previous phase (pbo/PP) compared with those on  
PP in previous phase (PP/PP):
•   Mean increase in pbo/PP group: 7.16 ng/mL (male);  
17 ng/mL (female) 
•   Mean changes in PP/PP group: -2.59 ng/mL (male);  
-3.07 ng/mL (female)
Poster presentations
Nasrallah et al19 rCT, DB, PC
13-week, parallel-group, 
dose-response study
514 Discontinuation due to TeAes:
• Pbo: 6%; PP groups: 4%
Mean weight and BMi change:
• PP 156 mg: +1.3 kg and 0.5 kg/m2
• PP 78 mg: +0.8 kg and 0.3 kg/m2
• PP 39 mg: +0.4 kg and 0.2 kg/m2
Mean (SD) increase in prolactin (ng/mL) from baseline to 
endpoint:
•   Women- [Pbo: -8.8 (7.36); PP 39 mg: 9.3 (5.49); 
PP 78 mg: 35.1 (6.70); PP 156 mg: 43.6 (7.73)]
•   Men- [Pbo: -2.1 (1.67); PP 39 mg: 4.0 (2.40); PP 78 mg: 6.8 
(2.18); PP 156 mg: 10.4 (2.24)]
Coppola et al29 One-year, open-label 
study evaluating long-term 
safety, tolerability, and 
pharmacokinetics of PP 234 mg  
monthly
212 A total of 184 pts (87%) experienced 1 TeAe.
27 pts (13%) discontinued due to TeAes.
11 pts (5%) discontinued due to serious TeAes.
No deaths were reported during the study.
The most frequent TeAes (in 5% patients) were:
•   Nasopharyngitis, insomnia, injection-site pain, headache, tachycardia
incidence of ePS occurred in 50 patients (23.6%)
Overall body weight increases of 7% in 65 patients (31%). Mean 
body weight increased by 3.9% from baseline to endpoint.
Prolactin-related adverse effects in 41 patients (19%). incidences 
were higher in women (32.8%) than men (14.3%)
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were not considered severe in intensity. Median prolactin 
levels remained elevated for the paliperidone treatment 
groups compared with median predose treatment values, 
whereas prolactin levels decreased to pretreatment values 
in the placebo patients (see Table 4). The percentage of 
patients with a . 7% increase in weight was reported to be 
6–8% of patients in the paliperidone groups versus 4% for 
placebo-treated patients. Although the authors considered 
this weight increase to be low, it was still up to twice that 
seen in the placebo patients, therefore may be of clinical 
significance and a potential cause of metabolic compli-
cations. In addition, significant mean increases in body 
weight and body mass index from baseline to endpoint 
were observed for the 156 mg dose (P # 0.001 for both 
measures) and increases for the 78 mg dose compared with 
placebo were P = 0.036 for body mass index and P = 0.059 
for weight (see Table 4). The incidence of increased heart 
rate was higher for paliperidone-treated patients (17%) 
than for placebo (8%), as was the incidence of orthostatic 
hypotension (9% versus 4%, respectively), although none 
of the latter were reported as adverse effects or symptom-
atic, and the incidence of tachycardia was low (,2%). 
In addition, although the study was not powered to assess 
safety, cardiac tolerability appeared to be good, with no 
patients on paliperidone experiencing QTc prolongation or 
a QTc . 450 msec during the study.14
In the small 13-week trial, the frequency of glucose-
related adverse effects was the same (2%) in the placebo and 
paliperidone groups.17 As in the previous study, clinically 
relevant weight increases (.7% from baseline to endpoint) 
were more common among patients in the paliperidone groups 
(78 mg 12%, 156 mg 10%, 234 mg 4%) compared with pla-
cebo (2%), although the percentage of people with clinically 
relevant weight increases did not rise with increasing dose. In 
addition, mean increases in weight from baseline to endpoint 
were modest, and ranged from 0.9 to 1.5 kg but did not appear 
to be dose-related (see Table 4). However, mean increases in 
prolactin levels from baseline to endpoint were seen in all 
paliperidone groups, and increases were larger for the 156 mg 
and 234 mg groups than for the 78 mg group in both women 
and men, suggesting a dose-related relationship. There were 
no clinically relevant changes in vital signs, electrocardiogram 
(ECG) recordings, or other clinical laboratory parameters, and 
local injection site   tolerability was reported to be good.
In the largest dose-response study, the incidence of 
TEAEs leading to study discontinuation was similar across 
Table 4 (Continued)
Authors Study details Number of 
patients (n)
Safety outcomes for paliperidone palmitate
Comparison with RLAI
Fleischhacker et al22 rCT, 53-week, parallel-group, 
noninferiority study of PP 
compared with rLAi
747
(included in 
safety analysis)
rates of TeAes:
• 76% in PP + pbo group
• 79% in rLAi + oral risperidone
rates of TeAes leading to discontinuation
• 7% in PP + pbo group
• 6% in rLAi + oral risperidone group
rates of serious TeAes:
• 29% in PP group versus 21% in rLAi group
incidences of ePS were similar in both groups except 
hyperkinesias: 
• 6% in PP group versus 10% in rLAi group
Mean (SD) change in body weight from baseline to endpoint: 
• PP group: -0.2 kg (6.01) versus 
• rLAi group: 0.8 kg (5.65)
Pandina et al23  rCT, DB, parallel-group, 
noninferiority study with rLAi
13 weeks
1214
(safety analysis 
set)
rate of TeAes: 
• PP (57.9%) versus rLAi (52.8%) 
insomnia (9.4% versus 6.7%), injection site pain (5.1% versus 
0.8%) and anxiety (4.3% versus 2.1%) occurred at 2% higher 
incidence in PP group than rLAi.
incidence of glucose-related TeAes (,1% patients), ePS, mean 
[SD] increases in body weight at endpoint (PP: 1.1 [3.36] kg, 
rLAi: 1.0 [3.14] kg) and injection site tolerability were similar in 
both groups. 
Abbreviations: DB, double-blind; eCG, electrocardiogram; ePS, extrapyramidal symptoms; iTT, intention to treat; PP, paliperidone palmitate; pbo, placebo; PC, placebo-
controlled; rC, randomized controlled trial; SD, standard deviation; TeAe, treatment emergent adverse effect.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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treatment groups (placebo 6.7%, paliperidone 6.1%–8%).18 
However, the incidence of serious TEAEs was higher in the 
placebo group (14%) than in the paliperidone groups (39 mg 
9.4%, 156 mg 13.3%, 234 mg 8%). The most commonly 
reported serious TEAEs for paliperidone were worsening or 
exacerbation of schizophrenia (4.9%) and psychotic disorder 
(2.9%), although these figures were lower than those reported 
for placebo (6.1% and 4.3%, respectively). Unlike the previ-
ous study, a weight increase of 7% or higher was found to 
occur more frequently with the higher doses of paliperidone 
(see Table 4). There were no clinically relevant changes from 
baseline in vital signs, ECG recordings, or other laboratory 
parameters (including fasting glucose levels and serum lipids) 
in the paliperidone groups. In addition, injection site toler-
ability was said to be good, with investigators rating injection 
site pain similar to that with placebo.
Safety in long-term therapy
Findings from the long-term relapse prevention study 
showed that weight increase occurred more frequently in 
patients treated with paliperidone palmitate (7%) than pla-
cebo (1%), as did the blood glucose increase in the paliperi-
done group (3%) versus placebo (1%).20 Mean weight, from 
transition baseline to the double-blind endpoint, increased 
by 1.9 kg for paliperidone-treated patients, but remained 
unchanged for placebo patients. Abnormal weight increases 
(7%) also occurred in twice as many paliperidone patients 
as placebo patients from both transition and double-blind 
baselines (see Table 4). There were no clinically relevant 
changes from transition baseline to the double-blind end-
point in extrapyramidal symptom rating scales and no 
reports of orthostatic hypotension or ECG changes during 
the double-blind phase (although ECG changes were seen 
in the transition and maintenance open-label paliperidone 
phases). In accordance with other studies, prolactin levels 
increased for the paliperidone group, again more in women 
than in men, while levels decreased in the placebo group 
(see Table 4). No other laboratory parameter changes 
were noted, and injection site tolerability was similar in 
all groups.20
Other safety data
The safety and tolerability of initiating treatment with pali-
peridone palmitate via either deltoid or gluteal injections 
were investigated in a study comparing the two adminis-
tration routes.28 This crossover trial included 252 stable 
outpatients randomly assigned 1:1:1 to three dose groups 
of paliperidone (see Table 4) and two treatment sequences 
including deltoid muscle injection (13 weeks), followed 
by gluteal muscle injection (12 weeks), or the reverse. The 
proportion of patients with injection-site pain appeared 
to be higher after deltoid administration compared with 
gluteal administration (41% deltoid, 26% gluteus), based 
on the 90% CI of investigator evaluations of the pres-
ence of local symptoms at the injection site. The overall 
incidence of TEAEs did not differ significantly between 
deltoid injections (period 1 = 64%, period 2 = 51%) and 
gluteal injections (period 1 = 63%, period 2 = 46%), and 
there was no dose-dependent increase in the incidence of 
TEAEs. Evaluation of pain by patients revealed slightly 
more intense pain following deltoid injections compared 
with gluteal injections for the 78 mg and 117 mg doses of 
paliperidone, but no difference was detected for the 156 
mg dose. There were no clinically significant changes in 
extrapyramidal symptom rating scales regardless of the 
injection site or the dose.28
Safety compared with active comparator
In the two noninferiority studies of paliperidone palmitate 
and RLAI, the overall rates of TEAEs were found to be 
similar between the two groups. In the first study, rates of 
TEAEs were 76% in the paliperidone group and 79% in the 
RLAI group,22 whereas in the second study, rates of TEAEs 
were 57.9% in the paliperidone group and 52.8% in the 
RLAI group.23 Therefore, neither drug can be associated 
with a higher incidence of adverse effects based on these 
results. In both studies, the incidence of extrapyramidal 
symptoms was similar in both groups, with the exception of 
hyperkinesias which was less common in the paliperidone 
group than in the RLAI group in the first study (6% versus 
10%, respectively).22 With regard to weight changes, weight 
actually decreased in the paliperidone palmitate group in 
the first study compared with RLAI (which caused a slight 
weight increase), whereas in the second study, mean body 
weight increases were similar at the endpoint between 
the two treatment groups (see Table 4). In addition, in the 
second study, there were no clinically relevant changes in 
vital signs or ECG, and the incidence of glucose-related 
TEAEs, as well as investigator assessments of the injec-
tion site, were similar in both treatment groups.23 Overall, 
it appears that both paliperidone palmitate and RLAI have 
comparable adverse effect profiles. However, the second 
study only lasted 13 weeks, and so long-term comparisons 
cannot be made. In addition, both studies are currently only 
available in poster format, thus not allowing for a thorough 
evaluation of the data.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Summary of safety data
In summary, paliperidone is relatively well tolerated but, like 
many other antipsychotics, and as expected from its pharma-
cological profile, it can cause weight gain and an increase in 
prolactin levels. Whether weight gain is dose-related or not 
is still debatable based on the current evidence. However, the 
rise in prolactin has been shown to be greater with higher 
doses. In all studies, there were no clinically relevant changes 
in vital signs, ECG recordings, or other clinical laboratory 
parameters, and local injection site tolerability was reported 
to be good. The majority of currently available trials are short-
term, therefore additional longer trials are required in order 
to assess paliperidone palmitate’s long-term safety profile, 
in particular with regard to changes in metabolic parameters 
because these may not be picked up in short-term studies. 
Paliperidone injection and RLAI were found to have com-
parable adverse effect profiles. Table 5 compares the adverse 
effects of paliperidone with other antipsychotic agents.
Discussion
Paliperidone palmitate has been shown to be effective in reduc-
ing PANSS total scores in both acute and maintenance treat-
ment of schizophrenia. Improvements in PANSS total scores 
observed in the majority of studies were greater with higher 
doses of paliperidone, suggesting a dose-response relationship. 
Paliperidone injection is generally well tolerated but can cause 
weight gain and dose-related raised prolactin levels. In two 
noninferiority studies comparing paliperidone with RLAI, 
paliperidone injection only proved to be noninferior to RLAI 
in one study. Paliperidone and RLAI were shown to have com-
parable adverse effects. Additional long-term   trials comparing 
paliperidone palmitate’s efficacy and safety with active com-
parators are required. The fact that some of the current data for 
paliperidone injection are only available as poster presentations 
is an important limitation for its evaluation.
Conclusion
Given the importance of treatment adherence in schizophre-
nia, and taking into consideration the compliance problems 
that often accompany the illness, long-acting antipsychotic 
injections are a valuable form of therapy. Paliperidone palmi-
tate once-monthly injections may be a useful alternative in 
a currently limited market. The recommended dosage regi-
men is 234 mg on day 1 followed by 156 mg a week later, 
both administered in the deltoid muscle. The recommended 
maintenance dose is 117 mg monthly, which may be adjusted, 
based on efficacy and tolerability, within a 39–234 mg 
range, administered in either the deltoid or gluteal muscle. 
Paliperidone palmitate has some advantages over available 
agents, including a faster onset of action than RLAI and the 
absence of a requirement for oral supplementation at the start 
of therapy. Therefore, it may be a suitable option in patients 
who refuse oral treatment. In addition, it is available in a 
wider variety of strengths than RLAI, allowing for a more 
specialized and patient-specific dose titration regimen. Since 
paliperidone can be given either in the deltoid or gluteal 
muscle after initiation has been established, this improves 
flexibility of administration. It also has the added advantage 
of not requiring refrigeration for safe storage. Furthermore, 
unlike with olanzapine pamoate, “post-injection syndrome” 
was not reported during the clinical trials with paliperidone, 
which makes it a suitable agent when a postinjection obser-
vation period is not practical.
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Table 5 Adverse effects of paliperidone compared to other antipsychotics
Drug QTc 
prolongation
Hypotension Sedation Weight 
gain
Metabolic 
syndrome
Extrapyramidal 
symptoms
Anticholinergic Prolactin 
elevation
Amisulpride + - - - + + - +++
Aripiprazole - - - +/- +/- +/- - -
Asenapine + - + - - + - +/-
Chlorpromazine ++ +++ +++ ++ ++ ++ ++ +++
Clozapine + +++ +++ +++ +++ - +++ -
Haloperidol +++ + + + + +++ + +++
Olanzapine + + ++ +++ +++ +/- + +
Paliperidone -/+ ++ + ++ ++ + + +++
Quetiapine ++ ++ ++ ++ ++ - + -
risperidone + ++ + ++ ++ + + +++
Sulpiride + - - + + + - +++
Abbreviations: +++, high incidence/severity; ++, moderate incidence/severity; +, low incidence/severity; -, very low incidence/severity. Adapted from The Maudsley 
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